REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.03
-0.23 (-2.48%)
At close: Sep 17, 2025, 4:00 PM EDT
9.21
+0.18 (1.99%)
After-hours: Sep 17, 2025, 5:52 PM EDT

REGENXBIO Statistics

Total Valuation

REGENXBIO has a market cap or net worth of $456.14 million. The enterprise value is $364.24 million.

Market Cap456.14M
Enterprise Value 364.24M

Important Dates

The next estimated earnings date is Wednesday, November 5, 2025, after market close.

Earnings Date Nov 5, 2025
Ex-Dividend Date n/a

Share Statistics

REGENXBIO has 50.51 million shares outstanding. The number of shares has increased by 10.99% in one year.

Current Share Class 50.51M
Shares Outstanding 50.51M
Shares Change (YoY) +10.99%
Shares Change (QoQ) +0.10%
Owned by Insiders (%) 8.02%
Owned by Institutions (%) 76.36%
Float 41.41M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.96
Forward PS 2.08
PB Ratio 2.13
P/TBV Ratio 2.13
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.34
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.13, with a Debt / Equity ratio of 1.27.

Current Ratio 3.13
Quick Ratio 3.03
Debt / Equity 1.27
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -5.52

Financial Efficiency

Return on equity (ROE) is -62.49% and return on invested capital (ROIC) is -20.73%.

Return on Equity (ROE) -62.49%
Return on Assets (ROA) -17.88%
Return on Invested Capital (ROIC) -20.73%
Return on Capital Employed (ROCE) -35.67%
Revenue Per Employee $441,309
Profits Per Employee -$497,368
Employee Count353
Asset Turnover 0.27
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -29.12% in the last 52 weeks. The beta is 1.17, so REGENXBIO's price volatility has been higher than the market average.

Beta (5Y) 1.17
52-Week Price Change -29.12%
50-Day Moving Average 8.78
200-Day Moving Average 8.22
Relative Strength Index (RSI) 49.37
Average Volume (20 Days) 510,676

Short Selling Information

The latest short interest is 5.14 million, so 10.17% of the outstanding shares have been sold short.

Short Interest 5.14M
Short Previous Month 5.47M
Short % of Shares Out 10.17%
Short % of Float 12.40%
Short Ratio (days to cover) 7.34

Income Statement

In the last 12 months, REGENXBIO had revenue of $155.78 million and -$175.57 million in losses. Loss per share was -$3.43.

Revenue155.78M
Gross Profit 128.43M
Operating Income -164.60M
Pretax Income n/a
Net Income -175.57M
EBITDA -148.75M
EBIT -164.60M
Loss Per Share -$3.43
Full Income Statement

Balance Sheet

The company has $323.30 million in cash and $271.69 million in debt, giving a net cash position of $91.90 million or $1.82 per share.

Cash & Cash Equivalents 323.30M
Total Debt 271.69M
Net Cash 91.90M
Net Cash Per Share $1.82
Equity (Book Value) 213.68M
Book Value Per Share 4.24
Working Capital 254.21M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$87.89 million and capital expenditures -$2.82 million, giving a free cash flow of -$90.71 million.

Operating Cash Flow -87.89M
Capital Expenditures -2.82M
Free Cash Flow -90.71M
FCF Per Share -$1.80
Full Cash Flow Statement

Margins

Gross margin is 82.44%, with operating and profit margins of -105.66% and -112.70%.

Gross Margin 82.44%
Operating Margin -105.66%
Pretax Margin -112.70%
Profit Margin -112.70%
EBITDA Margin -95.49%
EBIT Margin -105.66%
FCF Margin n/a

Dividends & Yields

REGENXBIO does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -10.99%
Shareholder Yield -10.99%
Earnings Yield -38.49%
FCF Yield -19.89%

Analyst Forecast

The average price target for REGENXBIO is $28.50, which is 215.62% higher than the current price. The consensus rating is "Strong Buy".

Price Target $28.50
Price Target Difference 215.62%
Analyst Consensus Strong Buy
Analyst Count 8
Revenue Growth Forecast (5Y) 50.49%
EPS Growth Forecast (5Y) -33.38%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

REGENXBIO has an Altman Z-Score of -1.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.78
Piotroski F-Score 3